If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

Share Price is delayed by 15 minutes
Get Live Data
930.00    -4.00 (-0.43%)
Bid:
922.00
Ask:
930.00
Spread: 8.00 (0.868%)
Market Cap: £254.55m
GHH Live PriceLast checked at - London Stock Exchange

Intraday Gooch & Housego Share Chart

Life Sciences Acquisition

8 Aug 2018 07:00

RNS Number : 1631X
Gooch & Housego PLC
08 August 2018
 

For immediate release

8 August 2018

 

 

 

 

Gooch & Housego PLC

("G&H" or the "Company")

 

Life Sciences Acquisition

 

 Further enabling G&H's move into system based products

 

 

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of optical components & systems, announces that it has acquired the entire issued share capital of VITL Ltd ('ITL" or "Integrated Technologies Limited") for a total consideration of up to £22.0 million. This acquisition expands the Company's presence in the life sciences sector and further enables G&H's move into system based products.

 

ITL

 

Founded in 1977, ITL is a UK based specialist in the design, development and manufacture of high-quality medical and in vitro diagnostic (IVD) devices.

 

ITL is a market leading supplier with an established group of long standing multi national customers. It provides full product development, design, manufacturing and after sale service for the commercialisation of medical diagnostic, analytical, precision electro-mechanical and laboratory instruments. ITL is headquartered in Ashford, Kent, with manufacturing sites in Ashford and Shanghai, China, plus a US client servicing capability based in Virginia, USA.

 

This acquisition enables G&H to take a significant step towards meeting its strategic objectives, including doubling the revenue of its life science business and accelerating the Company's move up the value chain, with all of ITL's sales coming from system based products. ITL's core group of electronic, software and mechanical engineers, provides an enhanced platform on which G&H can expand its systems capabilities.

 

Over time there are a number of potential benefits that will accrue from ITL becoming part of G&H. These include leveraging G&H's footprint in the US, China and Far East and combining the Company's photonic expertise with ITL's high level systems capability in order to provide a more attractive product offering to G&H's medical diagnostic customer base.

 

Terms of acquisition

 

The total consideration payable by G&H is up to £22.0 million. This comprises an initial cash consideration of £14.0 million, funded from existing resources, together with £1.4 million of new G&H shares. There is also a deferred contingent cash consideration of up to £8.0 million, based upon the performance of the business over the next two years. The Company has made an application to the London Stock Exchange for the 92,684 new Ordinary Shares to be admitted to trading on AIM. It is expected that admission will become effective on or around 14 August 2018.

 

The historical annual revenue of ITL was c.£10 million, adjusted operating profit was c.£1.5 million and the acquisition is expected to be earnings enhancing in the first full financial year of G&H's ownership. Historical gross assets were c£7 million.

 

 

Mark Webster, Chief Executive Officer of Gooch & Housego, commented:

"This acquisition provides a key step towards achieving our strategic aims of establishing 'critical mass' in our life sciences business and moving up the value chain, through a more systems based product portfolio.

"It means we are able to continue to diversify our business, allow G&H access to new high growth markets, as well as reducing, still further, dependency on the historically cyclical micro-electronic sector.

"ITL is a high quality business, with a long standing customer base, excellent engineering capabilities and a strong financial track record. 

"We are very much looking forward to working with the management, staff and customers of ITL."

 

 

For further information contact: -

 

 

 

Mark Webster / Andrew Boteler

Gooch & Housego PLC

01460 256440

Mark Court/ Sophie Wills

Buchanan

020 7466 5000

Patrick Robb / David Anderson

Investec Bank plc

020 7597 5970

 

 

 

 

 

 

 

Notes to editors

 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2. All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACQEVLBBVVFLBBQ
Date   Source Headline
3rd Dec 20137:00 amRNSPreliminary Results
26th Nov 20137:00 amRNSAcquisition of Constelex Technology Enablers Ltd
1st Nov 20137:00 amRNSNotification of Preliminary Results
29th Oct 201312:06 pmRNSHolding(s) in Company
15th Oct 201310:17 amRNSHolding(s) in Company
15th Oct 20137:00 amRNSAcquisition of Spanoptic Limited
8th Oct 201311:21 amRNSHolding(s) in Company
7th Oct 20137:00 amRNSFull-Year Trading Update
1st Oct 201311:52 amRNSHolding(s) in Company
18th Sep 20137:00 amRNSCapital Markets Day
9th Sep 20132:38 pmRNSHolding(s) in Company
25th Jul 20135:54 pmRNSHolding(s) in Company
25th Jul 20135:52 pmRNSHolding(s) in Company
12th Jul 20133:12 pmRNSDirector/PDMR Shareholding
12th Jul 20133:11 pmRNSDirector/PDMR Shareholding
12th Jul 20133:09 pmRNSDirector/PDMR Shareholding
12th Jul 20133:07 pmRNSDirector/PDMR Shareholding
12th Jul 20133:05 pmRNSDirector/PDMR Shareholding
11th Jun 20137:00 amRNSSales and Marketing drive
11th Jun 20137:00 amRNSInterim Report
9th May 20137:00 amRNSNotification of Interim Results
10th Apr 20137:00 amRNSNew Long Term Incentive Plan and grant of Awards
8th Apr 20137:00 amRNSHalf Year Trading Update
19th Mar 201310:44 amRNSAnnual Report and Accounts
15th Mar 201310:50 amRNSHolding(s) in Company
1st Mar 20134:09 pmRNSDirector/PDMR Shareholding
1st Mar 20134:05 pmRNSDirector/PDMR Shareholding
1st Mar 20134:03 pmRNSDirector/PDMR Shareholding
1st Mar 20134:01 pmRNSDirector/PDMR Shareholding
28th Feb 20137:00 amRNSResults of Annual General Meeting
27th Feb 201311:24 amRNSAIM Disclosure Update
27th Feb 20137:00 amRNSTrading Update
4th Feb 20133:00 pmRNSAdditional Listing
18th Jan 20132:12 pmRNSDirector/PDMR Shareholding
18th Jan 20132:11 pmRNSDirector/PDMR Shareholding
18th Jan 20132:09 pmRNSDirector/PDMR Shareholding
10th Jan 20133:00 pmRNSAdditional Listing
7th Jan 20137:00 amRNSValue Creation Plan Crystallises
13th Dec 20124:43 pmRNSHolding(s) in Company
27th Nov 20127:00 amRNSPreliminary Results
23rd Oct 20129:34 amRNSHolding(s) in Company
15th Oct 201211:02 amRNSHolding(s) in Company
5th Oct 20127:00 amRNSDirector change
4th Oct 20127:00 amRNSFull-Year Trading Update
25th Sep 20129:53 amRNSHolding(s) in Company
24th Sep 20122:09 pmRNSAdditional Listing
19th Sep 20128:47 amRNSAdditional Listing
19th Sep 20128:45 amRNSDirector/PDMR Shareholding
4th Sep 20122:14 pmRNSHolding(s) in Company
4th Sep 201210:20 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.